• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Impact of thyroid disease in patients with atrial fibrillation: Analysis from the JoFib registry
CONCLUSION: Despite having similar stroke and bleeding risks, patients with thyroid disease demonstrated meaningful differences in their baseline characteristics. Prospective studies are required to assess the influence of thyroid hormone fluctuations on the progression of AF.PMID:35145683 | PMC:PMC8818533 | DOI:10.1016/j.amsu.2022.103325
Source: Annals of Medicine - February 11, 2022 Category: Internal Medicine Authors: Hanna Al-Makhamreh Abdallah Al-Ani Dana Alkhulaifat Liza Shaban Neveen Salah Rusul Almarayaty Yazan Al-Huneidy Ayman Hammoudeh Source Type: research

Warfarin adherence and anticoagulation control in atrial fibrillation patients: a systematic review
CONCLUSIONS: While the available evidence is limited, this systematic review demonstrated a positive finding of the association between warfarin adherence and anticoagulation control in patients with AF.PMID:34982455 | DOI:10.26355/eurrev_202112_27642
Source: European Review for Medical and Pharmacological Sciences - January 4, 2022 Category: Drugs & Pharmacology Authors: M Ababneh S A Nasser A Rababa'h F Ababneh Source Type: research

Apixaban and rivaroxaban use for atrial fibrillation in patients with obesity and BMI ≥50 kg/m2
ConclusionsThis study demonstrated that apixaban and rivaroxaban in patients with a BMI ≥50 kg/m2 for treatment of NVAF may be safe and effective at preventing thromboembolic events and had no increased risk of bleeding. Although, findings should be interpreted with caution and confirmed with additional studies. This study contributes to the growing body of evidence that direct oral anticoagulants (DOACs) may be effective and safe to use for the treatment of NVAF in patients with BMI ≥50 kg/m2.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - December 13, 2021 Category: Drugs & Pharmacology Authors: Cavan P. O ’Kane, Juan Carlo O. Avalon, Jordan L. Lacoste, Wei Fang, Christopher M. Bianco, Laura Davisson, Kara L. Piechowski Tags: ORIGINAL RESEARCH ARTICLE Source Type: research

Apixaban and rivaroxaban use for atrial fibrillation in patients with obesity and BMI ≥50 kg/m2
ConclusionsThis study demonstrated that apixaban and rivaroxaban in patients with a BMI ≥50 kg/m2 for treatment of NVAF may be safe and effective at preventing thromboembolic events and had no increased risk of bleeding. Although, findings should be interpreted with caution and confirmed with additional studies. This study contributes to the growing body of evidence that direct oral anticoagulants (DOACs) may be effective and safe to use for the treatment of NVAF in patients with BMI ≥50 kg/m2.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - November 25, 2021 Category: Drugs & Pharmacology Authors: Cavan P. O ’Kane, Juan Carlo O. Avalon, Jordan L. Lacoste, Wei Fang, Christopher M. Bianco, Laura Davisson, Kara L. Piechowski Tags: ORIGINAL RESEARCH ARTICLE Source Type: research

B-po04-143 safety and feasibility of reactive atrial-based anti-tachycardia pacing algorithm in cardiovascular implantable electronic devices to suppress atrial fibrillation in patients with left atrial appendage closure device
Reactive atrial-based anti-tachycardia pacing (rATP) in CIED (cardiovascular implantable electronic devices) are effective in AF suppression. Uninterrupted systemic anticoagulation is mandated when these algorithms are activated to avoid stroke and systemic thromboembolism. However, the use of rATP algorithm in patients with left atrial appendage (LAA) closure device without ongoing anticoagulation has not been studied.
Source: Heart Rhythm - July 28, 2021 Category: Cardiology Authors: Rayan El-Zein, Jordan Luli, Ishmail Saccoh, Cody Carter, Mitchell Stelzer, Emily M. Gates, Zeryab Khan, Ankur N. Shah, James M. Kleman, Sreedhar R. Billakanty, Anish K. Amin, Nagesh Chopra Source Type: research

Adherence to the 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline on the Use of Oral Anticoagulant Agents in Middle Eastern Patients with Atrial Fibrillation: The Jordan Atrial Fibrillation (JoFib) Study
CONCLUSIONS: The current status of the utilization of OACs in Middle Eastern AF patients appears to be promising and is consistent with the 2019 focused update of the 2014 AHA/ACC/HRS guideline. This trial is registered with NCT03917992.PMID:33898065 | PMC:PMC8052172 | DOI:10.1155/2021/5515089
Source: International Journal of Vascular Medicine - April 26, 2021 Category: Cardiology Authors: Ayman J Hammoudeh Yousef Khader Nazih Kadri Eyas Al-Mousa Yahya Badaineh Laith Habahbeh Ramzi Tabbalat Hesham Janabi Imad A Alhaddad Source Type: research

Pages: 1  2  3  4  5  6